The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone

The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone

<b>Introduction</b>: A combination of elotuzumab, pomalidomide, and dexamethasone (EPd) was approved for the treatment of relapsed/refractory multiple myeloma (RRMM) following the ELOQUENT-3 phase II clinical trial. However, the clinical experience with this therapy is still limited. In...

Full description

Saved in:
Bibliographic Details
Main Authors: Hitomi Nakayama, Yoshinobu Aisa, Chisako Ito, Aki Sakurai, Tomonori Nakazato
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Hematology Reports
Subjects:
multiple myeloma
elotuzumab
pomalidomide
relapse/refractory
transplant ineligible
Online Access:https://www.mdpi.com/2038-8330/16/4/58
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2038-8330/16/4/58

Similar Items